A Placebo-Controlled Double-Blind Randomized Study of Venlafaxine in the Treatment of Depression in Dementia

Authors:
  • FRFábio Lopes Rocha
    Fábio Lopes Rocha
  • RMRodrigo Ávila de Melo
    Rodrigo Ávila de Melo
  • EVEstevão Alves Valle
    Estevão Alves Valle
  • JNJosé Júlio de Souza Neto
    José Júlio de Souza Neto
  • RBRodrigo Mendes Brega
    Rodrigo Mendes Brega
  • FSFrancisca Magalhães Scoralick
    Francisca Magalhães Scoralick
  • SSSilvana Araújo Silva
    Silvana Araújo Silva
  • FOFlaviana Martins de Oliveira
    Flaviana Martins de Oliveira
  • AJAntônio Luciano da Costa Júnior
    Antônio Luciano da Costa Júnior
  • VAViviane Xavier Faria Alves
    Viviane Xavier Faria Alves
  • ESEmília Sakurai
    Emília Sakurai
Publisher website
Google Scholar
Abstract
Background/Aims: To evaluate the efficacy and safety of venlafaxine in the treatment of major depression in dementia. Methods: Thirty-one outpatients who had dementia and major depression participated in this randomized, double-blind, placebo-controlled, 6-week, flexible dose clinical trial. The screening measures were Cornell Scale for depression in dementia, DSM-IV for depression and dementia and Mini-Mental State Examination. The outcome measures were response rate, Montgomery-Åsberg Depression Rating scale and Clinical Global Impressions. Results: The percentage of patients defined as Montgomery-Åsberg Depression Rating scale responders was approximately the same in the placebo and in the venlafaxine groups. Clinical Global Impressions showed no significant difference between the groups. The reasons for dropouts show borderline significance between the two groups. There was no statistically significant difference in the incidence of adverse events between the venlafaxine and placebo-treated groups. Conclusions: Our data do not support the hypothesis that venlafaxine improves mood in elderly demented patients.

This publication has 31 references indexed in Scilit: